1. Bender RA, Chabner BA (1982) Tubulin binding agents. In: Chabner B (ed) Pharmacologic principles of cancer treatment. Saunders, Philadelphia, pp 256–268
2. Brochure (1981) Vinzolidine, an investigational new drug. Eli Lilly Co., p 92 (on file with the Food and Drug Administration)
3. Budman DR, Schulman P, Marks M (1984) Phase I trial of vinzolidine (LY 104 208) given on an every two week schedule. Cancer Treat Rep 68: 979
4. Budman DR, Kreis W, Milazzo J, Schulman P, Allen S, Weiselberg L, Satterlee W, Vinciguerra V (1988) Phase I trial of i.v. vinzolidine (LY 104 208) on a two week dosing schedule. Proc Am Soc Clin Oncol 7: 55
5. Budman DR, Kreis W, Milazzo J, Schulman P, Allen S, Weiselberg L, Satterlee W, Vinciguerra V (1990) Phase I trial of i. v. vinzolidine (LY 104 208) on a two week dosing schedule. Invest New Drugs (in press)